These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159 [TBL] [Abstract][Full Text] [Related]
29. HIV vaccine: hopes and hurdles. Chhatbar C; Mishra R; Kumar A; Singh SK Drug Discov Today; 2011 Nov; 16(21-22):948-56. PubMed ID: 21889604 [TBL] [Abstract][Full Text] [Related]
30. HIV vaccine rationale, design and testing. Slobod KS; Coleclough C; Bonsignori M; Brown SA; Zhan X; Surman S; Zirkel A; Jones BG; Sealy RE; Stambas J; Brown B; Lockey TD; Freiden PJ; Doherty PC; Blanchard JL; Martin LN; Hurwitz JL Curr HIV Res; 2005 Apr; 3(2):107-12. PubMed ID: 15853717 [TBL] [Abstract][Full Text] [Related]
31. Neutralizing antibody responses to HIV-1 infection. Morris L IUBMB Life; 2002; 53(4-5):197-9. PubMed ID: 12120994 [TBL] [Abstract][Full Text] [Related]
32. Clinical experience with therapeutic AIDS vaccines. Bourinbaiar AS; Abulafia-Lapid R Expert Rev Vaccines; 2005 Jun; 4(3):289-304. PubMed ID: 16026245 [TBL] [Abstract][Full Text] [Related]
33. Application of the polyvalent approach to HIV-1 vaccine development. Hurwitz JL; Slobod KS; Lockey TD; Wang S; Chou TH; Lu S Curr Drug Targets Infect Disord; 2005 Jun; 5(2):143-56. PubMed ID: 15975020 [TBL] [Abstract][Full Text] [Related]
34. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Phogat S; Wyatt R Curr Pharm Des; 2007; 13(2):213-27. PubMed ID: 17269929 [TBL] [Abstract][Full Text] [Related]
35. [Design, development and successful application of safe and effective HIV therapeutic and prophylactic vaccines]. Abalaka JO Zhonghua Nan Ke Xue; 2005 Jan; 11(1):8-16. PubMed ID: 15704674 [TBL] [Abstract][Full Text] [Related]
36. HIV vaccines 1983-2003. McMichael AJ; Hanke T Nat Med; 2003 Jul; 9(7):874-80. PubMed ID: 12835708 [TBL] [Abstract][Full Text] [Related]
37. Viral sequence diversity: challenges for AIDS vaccine designs. McBurney SP; Ross TM Expert Rev Vaccines; 2008 Nov; 7(9):1405-17. PubMed ID: 18980542 [TBL] [Abstract][Full Text] [Related]
38. Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines. McBurney SP; Ross TM Curr Pharm Des; 2007; 13(19):1957-64. PubMed ID: 17627529 [TBL] [Abstract][Full Text] [Related]
39. A boost for the immune system. TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365925 [TBL] [Abstract][Full Text] [Related]
40. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Pantaleo G; Koup RA Nat Med; 2004 Aug; 10(8):806-10. PubMed ID: 15286782 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]